Please check your internet connection and try again.
## Clobazam (Oral Formulation)
### Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It acts as an antiepileptic drug (AED) used as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
### Primary Indications
Adjunctive therapy for seizures in Lennox-Gastaut Syndrome (LGS).
### Adult Dosing
* **Initiation:** 5 mg twice daily.
* **Titration:** Increase dose by 5 mg to 10 mg every week based on clinical response and tolerability.
* **Maintenance:** Usual dose is 10 mg to 20 mg twice daily.
* **Maximum:** 20 mg twice daily (40 mg total daily dose).
### Pediatric Dosing (2 to <10 years of age and <30 kg)
* **Initiation:** 0.5 mg/kg/day administered in two divided doses.
* **Titration:** Increase dose by 0.5 mg/kg/day every week based on clinical response and tolerability.
* **Maintenance:** Usual dose is 1 mg/kg/day divided into two doses.
* **Maximum:** 1 mg/kg/day (not to exceed 20 mg twice daily or 40 mg total daily dose).
### Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose adjustments are provided, but consider lower doses and slower titration.
* **Renal Impairment:** Use with caution. No specific dose adjustments are provided, but consider lower doses and slower titration.
### Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory impairment.
### Adverse Effects
* **Common:** Somnolence, decreased appetite, constipation, aggression, irritability, ataxia, drooling, vomiting.
* **Serious:** Suicidal ideation and behavior, severe drowsiness, withdrawal symptoms upon abrupt discontinuation, respiratory depression.
### Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other sedatives):** Increased risk of sedation, respiratory depression, and coma.
* **CYP2C19 Inhibitors (e.g., fluconazole):** May increase clobazam concentrations.
* **CYP2C19 Inducers (e.g., rifampin):** May decrease clobazam concentrations.
* **Other AEDs:** Monitor for changes in efficacy or toxicity.
### Monitoring
* Monitor for signs of somnolence and sedation, especially when co-administered with other CNS depressants.
* Monitor for behavioral changes and suicidal ideation.
* Assess for withdrawal symptoms if discontinuation is planned.
* Monitor seizure frequency and severity.
### Clinical Pearls
* Clobazam has a longer half-life than many other benzodiazepines, which may allow for less frequent dosing but also increases the risk of accumulation.
* Abrupt discontinuation can lead to withdrawal symptoms, including rebound seizures. Taper gradually when discontinuing.
* Due to the risk of somnolence, patients should be advised against operating heavy machinery or driving until they know how clobazam affects them.
***
*This information is intended for clinical use and does not substitute for professional medical advice. Always verify current prescribing information and consult with a healthcare professional for any specific patient care decisions.*
